AnaptysBio <Momenta< J&J $强生(JNJ)$ $摩蒙塔制药(MNTA)$ $AnaptysBio(ANAB)$查看全文
同写意2021-05-26 18:31
撰文丨道鸣
低分子量肝素类药品存在免疫原性并易引发HIT,目前已上市未经大量临床试验验证的仿制品,尚无足够证据证明其精准复制原研药品,这意味着其潜在的HIT风险难以预知和控制,故而在此呼吁,LMWHs原研药的仿制品替代存在的安全隐患,应该引起行业足够重视。
低分子量肝素(low-molec...查看全文
chuminhua2020-08-19 23:28
8/19,J&J$强生(JNJ)$ 宣布,已达成最终协议,以每股52.50美元现金(约合65亿美元)的价格收购Momenta Pharmaceuticals$摩蒙塔制药(MNTA)$ ,该交易扩大了其在免疫介导疾病中的地位,并使其有机会扩展管线至自身抗体驱动的疾病。 这项交易比Momenta 8月18日的收盘价溢价70%,其中包括Momenta...查看全文
产业链观察2020-08-19 19:39
药企并购▶2020-08-19,生物技术公司Momenta Pharmaceuticals,Inc.( Nasdaq: $摩蒙塔制药(MNTA)$ )是一家专注于发现和开发新颖的生物疗法以治疗罕见的免疫介导性疾病的生物技术公司,宣布已与 Johnson & Johnson 达成最终协议, Johnson & Johnson以每股52.50美元的全现金...查看全文
$Momenta Pharmaceuticals (MNTA)$ 内部交易: 2016-08-19,SVP & General Counsel,Leicher Bruce ,卖出,803普通股, $12.04
$Momenta Pharmaceuticals (MNTA)$ 内部交易: 2016-08-22,高级VP, Development and Chi,Roach James M. ,卖出,249普通股, $12.10
$Momenta Pharmaceuticals (MNTA)$ 内部交易: 2016-08-19,高级VP, Development and Chi,Roach James M. ,卖出,842普通股, $12.04
$Momenta Pharmaceuticals (MNTA)$ 内部交易: 2016-08-22,高级V.P., Research,Kaundinya Ganesh Venkataraman ,卖出,227普通股, $12.10
$Momenta Pharmaceuticals (MNTA)$ 内部交易: 2016-08-19,高级V.P., Research,Kaundinya Ganesh Venkataraman ,卖出,822普通股, $12.04
$Momenta Pharmaceuticals (MNTA)$ SC 13D/A [Amend] - General statement of acquisition of beneficial ownership Filed: 2016-08-10 AccNo: 0001104659-16-138659 Size: 204 KB 网页链接
$Momenta Pharmaceuticals (MNTA)$ S-8 - Securities to be offered to employees in employee benefit plans Filed: 2016-08-08 AccNo: 0001235010-16-000011 Size: 137 KB 网页链接
$Momenta Pharmaceuticals (MNTA)$ 10-Q - Quarterly report [Sections 13 or 15(d)] Filed: 2016-08-05 AccNo: 0001235010-16-000008 Size: 7 MB 网页链接
$Momenta Pharmaceuticals (MNTA)$ 8-K - Current report Filed: 2016-08-04 AccNo: 0001235010-16-000005 Size: 151 KBItem 2.02: Results of Operations and Financial ConditionItem 9.01: Financial Statements and Exhibits 网页链接
$Momenta Pharmaceuticals (MNTA)$ 美东时间 2016-08-04 09:00 Before Open:MOMENTA PHARMA Earning Release . Wall St EPS Est ($):-0.30. 网页链接